Regeneron Eyes Another Pipeline Target: Arcalyst In Gout
This article was originally published in The Pink Sheet Daily
Executive Summary
Fresh from a success with the approval of Eylea for wet AMD, Regeneron has another target in sight: Arcalyst (rilonacept) for prevention of gout flares in patients initiating uric acid lowering therapy. FDA has accepted a supplemental BLA for the drug.